By Adam Bonislawski

Belgian protein biomarker firm Pronota announced recently that it has successfully completed a proof of concept study for a diagnostic platform employing next-generation sequencing in the identification and quantification of proteins.

The study combined the use of aptamers — short, selectively binding oligonucleotide sequences — with NGS technology, binding the aptamers to target proteins and then sequencing the protein-bound aptamers to quantify the proteins.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.